Squarepoint Ops LLC Solid Biosciences Inc. Transaction History

Squarepoint Ops LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$2.38 - $3.77 $31,703 - $50,220	-13,321 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$3.49 - $5.51 $247,364 - $390,537	-70,878 Reduced 84.18%	13,321 $49,000
Q1 2021 May 17, 2021	BUY	$5.37 - $10.72 $452,148 - $902,613	84,199 New	84,199 $466,000
Q4 2020 Feb 16, 2021	SELL	$3.08 - $7.79 $37,268 - $94,259	-12,100 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$2.02 - $3.08 $24,442 - $37,268	12,100 New	12,100 $25,000
Q1 2020 May 15, 2020	SELL	$2.31 - $4.43 $171,408 - $328,719	-74,203 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$2.82 - $12.9 $209,252 - $957,218	74,203 New	74,203 $330,000
Q3 2019 Nov 14, 2019	SELL	$4.33 - $11.64 $56,723 - $152,484	-13,100 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$4.6 - $10.13 $60,259 - $132,703	13,100 New	13,100 $75,000
Q1 2019 May 15, 2019	SELL	$7.19 - $32.37 $175,910 - $791,964	-24,466 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$21.32 - $46.34 $91,505 - $198,891	4,292 Added 21.27%	24,466 $656,000
Q3 2018 Nov 14, 2018	BUY	$36.35 - $51.7 $733,324 - $1.04 Million	20,174 New	20,174 $952,000

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $29.8M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.